Liver Cirrhosis and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains

Why this is studied in Liver Cirrhosis

In cirrhosis, functioning liver tissue has been replaced by scar, and portal pressure rises as a result. Cell therapy is studied for anti-fibrotic and regenerative support, usually as a bridge rather than a substitute for transplantation. The liver's genuine regenerative capacity makes the rationale more biologically plausible here than in most indications — which is not the same as effective.

What HSCT means in this table

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

The numbers

Every figure below comes from one reproducible query (liver cirrhosis x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Evidence here is mid-maturity: a handful of Phase 3 or 4 registrations (3 of 21) sit above a much larger early-phase base.

Registrations do not all survive contact with recruitment — 7 completed here, 1 stopped early, giving a 5% attrition rate.

Median planned enrolment is 30 participants (largest single study: 500). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

9 countries host at least one site. China is the largest single contributor at roughly 42% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

The sponsor mix is academic (9 academic or hospital, 1 commercial among the most frequent lead sponsors).

• Xijing Hospital of Digestive Diseases — 2 records
• Air Force Military Medical University, China — 2 records
• Vinmec Research Institute of Stem Cell and Gene Technology — 2 records
• General Hospital of Chinese Armed Police Forces — 2 records
• Assiut University — 1 record
• National Center for Global Health and Medicine, Japan — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many HSCT studies for Liver Cirrhosis are recruiting right now?

1 of 21 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is HSCT an approved treatment for Liver Cirrhosis?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 21 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on HSCT for Liver Cirrhosis?

3 of 21 records carry a Phase 3 or Phase 4 label and 7 are marked completed. Registrations run from 2006 to 2025.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.